Libbs Farmacêutica

• NCT06034561

  Collaborator, Phase 2, Recruiting, 50 people, Sep 13, 2023

• NCT05920005

  Collaborator, Phase 3, Completed, 702 people, Jun 27, 2023

• NCT04622956

  Collaborator, Phase 1/2, Status unknown, 47 people, Nov 10, 2020

• NCT04230408

  Collaborator, Phase 2, Completed, 48 people, Jan 18, 2020

• Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients

  Collaborator, Phase 1, Completed, 142 people, Feb 24, 2014

Sources: clinicaltrials.gov

• Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis

  Fees or honoraria, Jul 6, 2026

Sources: pubmed.ncbi.nlm.nih.gov